EGFR and lung adenocarcinoma: Although molecular profiling was not the primary endpoint of this study, it is worth noting that our center was already performing EGFR mutational testing in early-stage resected lung adenocarcinoma during the study period (2016–2020), anticipating current precision medicine approaches.